Compare ADMA Biologics Inc (ADMA) vs First Solar, Inc. (FSLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs First Solar, Inc. — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while First Solar, Inc. trades at $224.49 (market cap $24.47B). The key difference: First Solar, Inc. is far larger — about 11.5× ADMA Biologics Inc's market cap, and First Solar, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FSLR | |
|---|---|---|
Market Cap | $2.13B | $24.47B |
Sector | Health | Technology |
52-Week High | $20.38 | $318.30 |
52-Week Low | $7.60 | $160.84 |
Enterprise Value | $2.20B | $22.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
First Solar (FSLR) trades at $227.72, up 1.4% with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with $5.22B revenue, 30.73% net margin, and positive cash flow trends. Recent earnings beat expectations in Q1 2026 but missed in previous quarters. Multiple class action lawsuits create significant headwinds, though Deutsche Bank recently upgraded the stock citing valuation discount.
The stock presents a valuation opportunity with P/E of 15.06 below industry averages, but legal risks and technical weakness suggest cautious optimism. Analyst consensus price target of $272.20 implies 19.5% upside potential, though investors must weigh strong profitability against ongoing litigation concerns and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
